Lynparza trial shows significant progression-free survival benefit for women with ovarian cancer
Access for Canadian women remains in jeopardy despite mounting evidence of significant clinical benefits of Lynparza.
Allergan successfully completes Tobira Therapeutics acquisition
Acquisition adds global rights to highly differentiated compounds to treat multi-factorial elements of NASH.
Daiichi Sankyo to commercialize two products formulated with SentryBond abuse-deterrent technology
MorphaBond is an abuse-deterrent formulation of extended release morphine using physical and chemical barriers, without the use of aversive agents or opioid antagonists.
Seasonal influenza vaccines market will hit $4.3 billion by 2025
Amendments to the national immunization schedules of the US and the UK, the expansion of egg-based quadrivalent seasonal influenza vaccines across Germany, Italy, France, and Spain, and the transition from egg-based to cell culture-based vaccines will ...
AmpliPhi Biosciences granted Small and Medium Enterprise status by EMA
Europe to be a key market for the company's phage-based therapies to treat bacterial infections in patients with unmet medical needs.
New report reveals the motivations and strategies behind drug innovators' decision to outsource
Two-thirds of pharmaceutical manufacturing is outsourced; preferred providers pick up largest share.
Repatha regresses atherosclerosis in patients with coronary artery disease
Nearly two-thirds of patients experienced plaque regression with Repatha on top of optimized statin therapy.
Need help with selecting a flowmeter?
Titan Enterprises offers online informative and unbiased guidance document.
Biogen boosts the executive management team of its spin-off hemophilia company
The spin-off of Bioverativ is on track to be completed in early 2017.